Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
Blokirali ste korisnika/cu @antonynewton001
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @antonynewton001
-
Antony Newton proslijedio/la je Tweet
We’re excited to be at the
@AACR Advances in Liquid Biopsies conference. Please get in touch if you would like to meet our medical team and hear more about our#liquidbiopsy platform and our test relevant to the care of patients with advanced#NSCLChttps://tinyurl.com/t3n4zghHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Antony Newton proslijedio/la je Tweet
Nitzan Rosenfeld, CSO and co-founder of Inivata, describes the impact of
#lungcancer on his family life and the personal motivations behind his work developing pioneering#liquidbiopsy technology. Read the full interview here https://tinyurl.com/y5z66nbg pic.twitter.com/cEj64m0mKd
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Antony Newton proslijedio/la je Tweet
This is a Pfizer-funded study for
#lorlatinib but same study methodology could be applied to look at#drugresistance to other targeted therapies in onocology, says .@Inivata CEO. Ramp up in these deals expected over next 12 months.https://twitter.com/fwmedtech/status/1189477438587392001 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Antony Newton proslijedio/la je Tweet
Inivata to Employ Liquid Biopsy Test in EORTC Phase II NSCLC Study of Lorlatinibhttps://www.genomeweb.com/cancer/inivata-employ-liquid-biopsy-test-eortc-phase-ii-nsclc-study-lorlatinib?utm_source=addthis_shares#.Xbh61BO8WFI.twitter …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Invision First-Lung Liquid Biopsy Test selected by EORTC for a Pfizer funded trial of lorlatinib. Use for selection and monitoring will help understanding of resistance and inform future strategies for combination therapy. https://lnkd.in/d9VzCYG
#inivata#liquidbiopsyHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Antony Newton proslijedio/la je Tweet
Our VP of Business Development
@antonynewton001 speaking at the Precision Lung Cancer Summit on the#InVision platform and how its high sensitivity can assist in areas such as enrolling patients for trials and the early identification of#immunotherapy response#liquidbiopsypic.twitter.com/fAGiLOaZo3
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Antony Newton proslijedio/la je Tweet
Earlier today Inivata’s
@antonynewton001 presented on the sensitivity of the#InVision#liquidbiopsy platform - recently we shared data showing how the platform could also help predict patient response to immune checkpoint inhibitors in#NSCLC - read more:http://bit.ly/31DjeiZHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Antony Newton proslijedio/la je Tweet
Going to the Precision Lung Cancer Summit 2019 next week? So are we! We’re always interested in hearing about opportunities for collaboration and partnering with our
#liquidbiopsy platform. More info here https://www.inivata.com/events/precision-lung-cancer-summit-2019/ …@antonynewton001Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Antony Newton proslijedio/la je Tweet
#Liquidbiopsy leader@Inivata and collaborators at@CHUdeToulouse and@Inserm#Cancer Research Center of Toulouse (CRCT) have published a novel approach to predicting patient response to#immunecheckpointinhibitors in advanced non-small cell#lungcancer.https://www.exosome-rna.com/novel-approach-based-on-invision-liquid-biopsy-platform-predicts-response-to-immune-checkpoint-inhibitors/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Antony Newton proslijedio/la je Tweet
Pleased to have published a new approach predicting patient response to immune checkpoint inhibitors in advanced NSCLC in the Lung Cancer journal with University of Toulouse and
@Inserm@GuibertNicola31@crctoncopole@CHUdeToulouse@IUCTOncopoleICR https://tinyurl.com/y2559x79 pic.twitter.com/RDhFO5MZ7E
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Antony Newton proslijedio/la je Tweet
Novel approach based on our InVision® liquid biopsy platform identifies NSCLC patients who are most likely to respond to treatment with PD1 inhibitors. Read more here http://tinyurl.com/y2559x79
#liqudibiopsy#invision#NSCLCpic.twitter.com/r9ItGWR9XH
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Antony Newton proslijedio/la je Tweet
Presenting new data
#ESMO19. Together with our valued collaborators we are transforming#nsclc clinical cancer care with#liquidbiopsypic.twitter.com/Bz3OyuFE4W
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Antony Newton proslijedio/la je Tweet
Emma
@egfgreen85 from our clinical team and Tony from BD busy at#ESMO19 this weekend. If you’d like to meet with the team, please let us know#liquidbiopsy#nsclc#genomicspic.twitter.com/kkr4PqX883
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Antony Newton proslijedio/la je Tweet
This year
@HopkinsMedicine recognized Eniko Papp Ph.D to reflect the high quality of research she has completed. Very proud!pic.twitter.com/GrNRY4nLT0
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.